Dapagliflozin Plus Exenatide: Better Weight Loss Together?


What do you get when you combine an SGLT2 inhibitor and a GLP-1 receptor agonist into therapy for 1 diabetes patient?

Sodium glucose cotransporter 2 (SGLT2) inhibitors act in the body independent of insulin level. Glucagon-like peptide-1 (GLP-1) receptor agonists, on the other hand, are insulin dependent. Both classes are observed to promote weight loss as a secondary outcome to reducing hyperglycemia. Little is known, though, about whether the different mechanisms of action produce additive or synergistic effects on weight.

Combination therapy with an SGLT2 inhibitor and a GLP-1 receptor agonist:

A. Is safe and well tolerated
B. Achieves double the weight loss of an SGLT2 inhibitor alone
C. Is additive with respect to its effects on weight loss.
D. All of the above
E. None of the above
Related Videos
Vlado Perkovic, MBBS, PhD | Credit: George Institute of Global Health
Should We Reclassify Diabetes Subtypes?
What Should the American Academy of Physician Associates Focus on in 2025?
GLP-1 Agonist Safety Risks and Obesity Stigma with Kevin Peterson, MD, MPH
Video 8 - "Pathophysiology of Hypercortisolism"
Video 7 - "Evolving Perception of Autonomous Adrenal Hypercortisolism "
A panel of 5 experts on Cushing's syndrome
A panel of 5 experts on Cushing's syndrome
Laxmi Mehta, MD | Credit: American Heart Association
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
© 2024 MJH Life Sciences

All rights reserved.